To systematically evaluate the clinical efficacy of probiotics combined with antiviral drug entecavir in the treatment of hepatitis B cirrhosis and its effect on liver function and the degree of liver fibrosis.

The high-quality literature on the randomized controlled study of probiotics combined with entecavir in the treatment of hepatitis B cirrhosis published in Chinese and foreign databases such as CNKI, Wanfang, China biomedical literature service system, PubMed and EMBase from the establishment of the database to January 2022 were searched. The literatures were screened according to the inclusion and exclusion criteria. The quality of the 14 articles finally included was analyzed, and the collected data were meta analyzed using the statistical software revman 5.4.

A total of 14 randomized controlled studies (1 222 patients) were included in this study for statistical processing. Probiotics combined with entecavir in the treatment of hepatitis B cirrhosis could improve the total effective rate of patients (OR=5.62, 95% CI: 2.75-11.48, Z=4.74, P<0.000 001); Probiotics combined with entecavir had a higher negative conversion rate of HBV-DNA (OR=2.43, 95% CI: 1.39-4.25, Z=3.12, P<0.01). Liver function index: ALT (OR=-8.74, 95% CI: -12.56~-4.91, Z=4.48, P<0.01); AST (OR=-24.27, 95% CI: -33.5~-15.03, Z=5.75, P<0.01); ALB (OR=4.17, 95% CI: 3.32-5.02, Z=9.62, P<0.01). Liver fibrosis index: HA (OR=-33.09, 95% CI: -40.08~-25.35, Z=11.48, P<0.01); LN (OR=-20.47, 95% CI: -23.03~-17.90, Z=15.66, P<0.01).

Probiotics combined with entecavir in the treatment of hepatitis B cirrhosis can improve the clinical efficacy of patients with hepatitis B cirrhosis and the negative conversion rate of hepatitis B HBV-DNA, and improve the liver function and the degree of liver fibrosis.